Eradication of Helicobacter pylori Increases Ghrelin mRNA Expression in the Gastric Mucosa by Lee, Eon Sook et al.
INTRODUCTION
Helicobacter pylori infection is an emerging global health
problem and is regarded as a major cause of chronic gastri-
tis, peptic ulcer and gastric adenocarcinoma (1, 2). It not only
is the major pathogen of the gastrointestinal tract but also
may be responsible for dyspeptic symptoms and reduced ap-
petite (3, 4). Recent studies have shown that the eradication
of H. pylori may be associated with improved appetite and
weight gain (5, 6). However, the underlying mechanism is
not well understood. 
Ghrelin is a 28-amino-acid peptide that stimulates appe-
tite and is secreted mainly in the stomach (7-9). Some stud-
ies have demonstrated that H. pylori infection causes a mark-
ed reduction in gastric and plasma ghrelin (10). Ghrelin has
been suggested as a possible mediator between H. pylori in-
fection and appetite. Other studies have supported this hypo-
thesis by demonstrating that eradicating H. pylori increases
ghrelin production (11, 12). However, these studies were li-
mited in that they were designed as observational studies,
and the enrolled subjects had inflammations of varying sever-
ity, ranging from gastritis to more serious inflammatory con-
ditions, such as peptic ulcers and occasionally gastric cancer.
Because inflammation influences ghrelin production (12),
the relationship between H. pylori eradication and ghrelin
production might have been biased by these inflammatory
changes. Furthermore, these studies did not control for gas-
trointestinal symptoms such as pain and indigestion, which
may also affect appetite and ghrelin production (13). To elu-
cidate the effects of H. pylori eradication on ghrelin produc-
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Eradication of Helicobacter pylori Increases Ghrelin mRNA Expression
in the Gastric Mucosa
It has been suggested that Helicobacter pylori eradication may influence produc-
tion of some peptides in the stomach, which can affect appetite. This hypothesis is
controversial. To verify the hypothesis, we conducted this randomized controlled
trial using H. pylori infected subjects without any gastrointestinal symptoms. The
treatment group received triple H. pylori eradication therapy for 7 days and the con-
trol group received no medication. We measured ghrelin, obestatin and the tumor
necrosis factor-a (TNF-a) mRNA levels in endoscopic biopsy specimens and the
changes from baseline to follow-up. The plasma active n-octanoyl ghrelin and obes-
tatin levels were measured in both groups. The ghrelin/obestatin ratios in plasma
and gastric mRNA expression were calculated at baseline and follow-up. Ghrelin
mRNA expression in the fundic mucosa after H. pylori eradication increased signif-
icantly compared to the control group (4.47±2.14 vs. 1.79±0.96, P=0.009), inde-
pendent of inflammatory changes. However, obestatin mRNA expression decreased
in the antral mucosa (-0.57±1.06 vs. 0.41±0.72, P=0.028). The treatment group
showed a marginal increase (P=0.060) in plasma ghrelin/obestatin ratio. The TNF-
a mRNA expression also decreased significantly with treatment. This randomized
controlled trial demonstrates that H. pylori eradication increases ghrelin mRNA ex-
pression, independent of inflammatory cell changes.
Key Words : Ghrelin; Helicobacter pylori; Appetite; Gastritis
Received : 22 October 2008
Accepted : 24 March 2009
ⓒ 2010 The Korean Academy of Medical Sciences.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial
License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, 
distribution, and reproduction in any medium, provided the original work is properly cited.tion, more sophisticated investigations controlling these bia-
ses are needed. 
Zhang et al. (14) reported that the ghrelin gene also encodes
the obestatin peptide. It was initially reported that obestatin
functioned against ghrelin; for example, obestatin reduced
refeeding, whereas ghrelin stimulated food intake and gastric
transit. It is possible that ghrelin and obestatin work together
to regulate homeostasis and body weight (15, 16), although
their mutual action is still disputed. In addition, obestatin
tends to be lower in gastrectomy subjects (16). These data
suggest that eradication therapy for H. pylori infection could
modify the production of both obestatin and ghrelin. How-
ever, there is no data regarding an association between H. pylori
infection and obestatin, and no clinical trials verifying the
relationship. Therefore, we evaluated ghrelin and obestatin
production after treating H. pylori infections, through a ran-
domised, controlled trial using healthy volunteers without
gastrointestinal symptoms or peptic ulcers. 
MATERIALS AND METHODS
Subjects 
We recruited 65 volunteers with no gastrointestinal sym-
ptoms. Because ulcer healing is another important factor
affecting appetite and ghrelin production, as suggested by
our previous study (17) and can act as a bias in this study,
we recruited only healthy volunteers not having peptic ulcers.
The study was approved by the Institutional Review Board
of Inje University, Ilsan-Paik Hospital in Korea. Written in-
formed consent was obtained from the patients before their
participation. Initially, all the participants underwent upper
gastrointestinal endoscopy. The exclusion criteria were as
follows: age <20 yr; age >70 yr; pregnancy; abnormal gas-
tric lesions, including ulcers or cancer; duodenal ulcers; liver
disease; renal impairment; previous gastrointestinal surgery;
history of H. pylori eradication; and drug abuse (10, 18). After
an initial endoscopy, seven patients were excluded because
of peptic ulcers, 26 were excluded because they were H. pylori-
negative and two refused to participate. The remaining 30
subjects with H. pylori were randomly assigned to treatment
and control groups. The appetites of all subjects were esti-
mated using a Visual Analog Scale (VAS) of appetite that has
been shown to be reliable and valid for Koreans (19).
Endoscopy
To avoid the effects of diurnal hormone variation, endo-
scopy was performed after an overnight fast between 08:00
and 10:00. Two biopsy specimens were taken from the mid-
portion of the fundus along the greater curvature, and two
were taken from intact mucosa in the gastric antrum, 2 cm
proximal to the pylorus. The four samples were transferred
to tubes containing TRIzol
� (Gibco, Long Island, NY, USA)
and stored immediately at -70℃ until assayed. Two addi-
tional endoscopic biopsies were taken. One sample was fixed
in 10% formalin and embedded in paraffin for histological
assessment and the other sample was used for the rapid ure-
ase test (CLO test: Ballard Medical Products, Draper, UT,
USA) to detect H. pylori infection. All of the procedures were
repeated at the time of the second endoscopy.
Treatment of H. pylori infection and determination of
plasma active ghrelin, obestatin and TNF-a concentrations
The treatment group received triple therapy consisting of
a twice-daily regimen of 20 mg of esomeprazole, 1,000 mg
of amoxicillin and 500 mg of clarithromycin for 7 days. The
control group did not receive any prescription and was direct-
ed not to take any medication. Both groups underwent a se-
cond endoscopy 5 weeks later. All the examiner including
pathologist or endoscopist were blind to subject group iden-
tity. 
Blood samples were taken between 08:00 and 10:00, after
an overnight fast. The sample was transferred into a chilled
tube containing EDTA-2Na, centrifuged immediately and
stored at -70℃until assayed. The sample designated for gh-
relin analysis was acidified with 50 mL of 1 NHCl and 10 mL
of phenylmethylsulfonyl fluoride (PMSF) were added at 1 mL
of plasma. These samples were measured in duplicate. The
plasma active octanoylated form of ghrelin concentration was
measured using a radioimmunoassay kit (Linco Research, St.
Charles, MO, USA). The plasma obestatin was measured us-
ing a radioimmunoassay kit (Phoenix Pharmaceuticals, Bel-
mont, CA, USA). The inter- and intra-assay coefficients of
variation were 13.7 and 9.5% for ghrelin and less than 12%
and less than 5% for obestatin, respectively.
RNA isolation
The RNA was recovered using a standard reported proce-
dure. The RNA was precipitated with isopropanol, and the
pellet was washed with 70% ethanol, air-dried and dissolved
in sterile diethylpyrocarbonate-treated water. The concen-
tration and purity of the RNA were determined using spec-
trophotometry (Ultrospec
� 1100 Pro; Amersham Pharma-
cia Biotech, Buck, UK) to measure the optical density ratio
at 260 and 280 nm.
Real-time RT-PCR of ghrelin, obestatin and TNF-a mRNA
One microgram of total RNA was used as a template to
generate cDNA by using M-MLV reverse transcriptase (Super
Bio, Suwon, Korea) with random hexamer priming. The re-
sultant cDNA was amplified using an Exicycler (Bioneer,
Seoul, Korea). Real-time PCR analysis was carried out with
SYBR
� Premix Ex Taq
TM (TaKaRa Bio, Tokyo, Japan) and
266 E.S. Lee, Y.S. Yoon, C.-Y. Park, et al.specific primers. The sequences of primers were as follows:
Ghrelin: 5′ -ATG CTC TGG CTG GAC TTG-3′ (sense) and
5′ -TCT GCT TGA CCT CCA TCT T-3′ (antisense; ACC
No. NM_016362; product size, 155 bp); Obestatin: 5′ -CAG
AGG ATG AAC TGG AAG TC-3′ (sense) and 5′ -CAG
AGG ATG TCC TGA AGA AA-3′ (antisense; ACC No.
NM_016362; product size, 118 bp); and TNF-a: 5′ -CTT
CTG GCT CAA AAA GAG AA-3′ (sense) and 5′ -GTC
AGG GAT CAA AGC TGT AG-3′ (antisense; ACC No.
BC 028148; product size, 189 bp). The gene mRNA levels
were normalized using b-actin. 
Histology
The biopsy samples were treated in a standard manner, and
neutrophil and mononuclear cell infiltration were assessed
using an updated Sydney system (20). Neutrophil infiltra-
tion into the lamina propria was scored on a scale of 0 to 3,
as described by the Sydney system. Mononuclear cell infil-
tration was determined as described above. The presence of
H. pylori in the biopsy material was determined histologi-
cally using a Giemsa stain. After 5 weeks, the same histo-
logical assessments were repeated. Histological evaluations
were performed by a well-trained pathologist who was blind
to the treatment, endoscopic diagnosis and H. pylori infec-
tion status. 
Statistical analysis
The data are expressed as mean±SD. A Student’s t-test
was used to compare the baseline characteristics and their
changes between the treatment and control groups. Analysis
of variance (ANOVA) was used to compare the expression of
ghrelin mRNA and TNF-amRNA according to the changes
of neutrophil infiltration, and a Student’s t-test was used ac-
cording to the changes of mononuclear cell infiltration. A
paired t-test was used to compare the ghrelin/obestatin ratio
in the plasma and gastric mRNA expression measured before
and after treatment. Multiple regression analysis was used
to assess the effects of H. pylori eradication on ghrelin produc-
tion by the gastric mucosa, adjusted by the weight change
and change in neutrophil or mononuclear cell infiltration. A
value of P<0.05 was considered statistically significant. 
RESULTS
No initial differences between the treatment and control
groups were observed with regard to the baseline character-
istics including age, body mass index (BMI), appetite, plas-
ma levels of ghrelin and obestatin, ghrelin, obestatin and
TNF-a mRNA expression levels in the gastric mucosa, and
neutrophil and mononuclear cell infiltration (Table 1). At the
5-week follow-up, three subjects from the treatment group
and two from the control group withdrew. Three more peo-
ple from the treatment group were excluded from the final
assessment because they were still H. pylori-positive after tre-
atment. Two from the control group were excluded for tak-
ing a drug that affects appetite (Fig. 1). 
Ghrelin mRNA expression in the gastric fundic mucosa
increased significantly in the treatment group compared with
the control group (4.47±2.14 vs. 1.79±0.96, P<0.01). As
shown in Fig. 2, gastric ghrelin mRNA expression increased
substantially with treatment for all subjects in the treatment
group but showed inconsistent or minor changes in the con-
trol group (Fig. 3). The plasma active ghrelin level in pati-
ents who received eradication drugs did not show a signifi-
cant change compared with the control group (2.63±6.23
vs. -0.70±9.37, P=0.374). Similarly, a comparison of the
VAS scores of hunger (P=0.767) and BMI (P=0.198) between
the treatment and control groups failed to demonstrate sta-
tistically significant differences. Obestatin mRNA expres-
sion in the gastric antral mucosa decreased after H. pylori erad-
ication in the treatment group but not in the control group
(-0.57±1.06 vs. 0.41±0.72, P=0.028). Obestatin mRNA
expression in the gastric fundic mucosa did not change in either
group (Table 2).
TNF-a mRNA expression in the gastric mucosa decreased
after H. pylori eradication (P=0.005, Table 2). Neutrophil
and mononuclear cell infiltration decreased significantly in
the treatment group after H. pylori eradication (P<0.001 and
P<0.001, respectively), whereas the values did not change
in the control group. 
We assessed the effect of inflammatory changes on ghrelin
production by the gastric mucosa. Ghrelin mRNA expres-
sion increased with a decrease in mononuclear cell infiltra-
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Parameters
Treatment
group
(n=9)
Control
group
(n=11)
P
value
Age (yr) 44.89±12.18 45.82±13.42 NS
Sex-female (%) 66.7 81.8 NS
BMI (kg/m
2) 24.47±2.60 22.24±2.10 NS
Waist circumference (cm) 82.44±7.28 78.82±6.16 NS
Total cholesterol (mg/dL) 180.00±27.48 174.91±24.66 NS
Glucose (mg/dL) 93.33±13.01 84.09±11.28 NS
Triglyceride (mg/dL) 141.00±53.58 110.18±133.36 NS
VAS of hunger (mm) 42.6±24.2 36.2±24.3 NS
Plasma ghrelin at entry (pg/mL) 18.64±5.08 20.96±8.08 NS
Plasma obestatin at entry (pg/mL) 8.04±1.42 7.98±1.89 NS
Inflammatory cell infiltration of the stomach
Neutrophils 2.33±0.71 2.73±0.47 NS
Mononuclear cells 2.89±0.33 2.91±0.30 NS
Atrophy 0.33±0.50 0.40±0.70 NS
Lymphoid 0.44±0.53 0.91±0.94 NS
Metaplasia 0.44±0.73 0.73±1.01 NS
Table 1. Baseline characteristics of the study population at entry*
*Data are the mean±SD. 
VAS of hunger, Visual analogue scale of hunger; BMI, body mass index.tion (P=0.046, Table 3), but not with the changes in infil-
trating neutrophils. According to the multiple regression
analysis, which excluded possible confounding factors such
as inflammations and weight change, the eradication of H.
pylori was an important factor related to increased ghrelin
mRNA expression, regardless of inflammation (P=0.004,
not shown in the Tables).
There was no significant difference in the ratio of ghrelin
expression to obestatin expression in the plasma or gastric mu-
cosa between before and after H. pylori eradication (Table 4).
DISCUSSION
This study showed a significant increase in ghrelin mRNA
expression in the gastric mucosa after H. pylori eradication.
The obestatin mRNA expression level in the gastric antrum
decreased after H. pylori eradication. The changes of plasma
active ghrelin and obestatin in the treatment group were si-
milar to the control group. The plasma ghrelin/obestatin ra-
tio of the treatment group changed insignificantly from 2.31
±0.44 to 3.01±1.00 (P=0.06). 
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Subjects (n=65)
Gastrofiberscope
Helicobacter positive (n=30)
Helicobacter eradication (+) (n=15)
Follow up (n=9) Follow up (n=11)
Treatment fail (n=3)
Follow loss (n=3)
Follow loss (n=2)
Treatment  (n=2)
Peptic ulcer (n=7)
Helicobacter negative (n=26)
Refuse (n=2)
Helicobacter eradication (-) (n=15)
Fig. 1. Flow chart of the study.
Changes in variables
�
Treatment
group
(n=9)
Control
group
(n=11)
P
value
�
Ghrelin mRNA expression- 4.47±2.14 1.79±0.96 0.009
fundus (%)
Ghrelin mRNA expression- 0.26±1.06 0.44±0.77 NS
antrum (%)
Plasma ghrelin (pg/mL) 2.63±6.23 -0.70±9.37 NS
Obestatin mRNA expression- 3.90±2.29 2.38±1.32 NS
fundus (%)
Obestatin mRNA expression- -0.57±1.06 0.41±0.72 0.028
antrum (%)
Plasma obestatin (pg/mL) 0.13±4.55 7.51±26.77 NS
TNF-a mRNA expression- -1.75±0.41 -0.05±1.56 0.005
fundus (%)
Neutrophil infiltration -2.22±0.67 -0.18±0.40 <0.001
Mononuclear cell infiltration -0.89±0.33 0.00±0.00 <0.001
BMI (kg/m
2) -0.25±0.30 0.09±0.75 NS
Appetite-VAS score 1.41±3.12 0.96±3.45 NS
Table 2. The change in ghrelin, obestatin, TNF-a, and inflamma-
tory cells of the treatment group after intervention or 5 months
later*
*Data are the mean±SD; 
� The changes of variables indicate the chang-
ed values measured from baseline to 5 weeks. The treatment group
received H. pylori eradication therapy during the 1st week. However,
the control group did not; 
� The P value was determined using the Stu-
dent’s t-test.
TNF-a, tumor necrosis factor-a; BMI, body mass index; VAS, visual ana-
logue scale.
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Fig. 2. The ghrelin mRNA expression level of gastric mucosa bet-
ween baseline and 5 weeks later in the group with or without H.
pylori eradication. *P<0.001 by paired t test; 
� P<0.05 by t-test. The
changes of ghrelin mRNA expression levels in the gastric mucosa
from baseline to 5 weeks later were compared in each group.Many researchers reported that H. pylori infection causes a
marked reduction in plasma ghrelin levels (21). The alter-
ation of plasma gastric originated appetite-controlling hor-
mones may contribute to the changes of appetite or dyspep-
tic symptoms in people with H. pylori infections. Therefore,
H. pylori infection is considered as an important factor in re-
duced appetite. Additionally, there is some evidence that an
improvement in dyspeptic symptoms occurred among pati-
ents with non-ulcer dyspepsia when H. pylori was eradicated
(21). Interestingly enough, the increased appetite as a results
of H. pylori eradication may support the theory that the cure
from H. pylori infections is associated with weight gain (6).
However, the results of other studies have either been incon-
sistent or failed to show that ghrelin mediates the association
between increased appetite and H. pylori eradication (18, 22).
We conducted this randomised controlled trial to better con-
trol a possible confounders and demonstrate a clearer associ-
ation between appetite and H. pylori eradication. 
Some authors suggest that inflammation of the gastric
mucosa is the one of the important mechanisms of H. pylori
induced change of ghrelin production. Isomoto et al. showed
that greater inflammation in an H. pylori-infected gastric mu-
cosa resulted in less ghrelin production (18). Previous stud-
ies on this issue recruited subjects with peptic ulcers or sto-
mach cancer. But peptic ulcers and cancer are conditions with
severely inflamed mucosal layers. They may be caused by
other factors than H. pylori infection. So the change in ghre-
lin production by H. pylori eradication in these previous stu-
dies might be biased by the severe inflammation of these dis-
eases. We also found that ulcer healing was a more impor-
tant factor in ghrelin production than H. pylori eradication
(17). Therefore, we recruited healthy subjects without pep-
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Changes in cells
Change in 
ghrelin mRNA
expression
Change in
plasma ghrelin
(pg/mL)
Change in
TNF-a mRNA
expression
Change in neutrophils
0 (n=9) 1.98±0.80 -3.58±7.02 -0.06±1.75
�
-1 (n=3) 3.36±4.33 10.40±6.80 -0.57±1.03
�
Over -2 (n=8) 3.94±1.64 2.13±6.46 -1.75±0.44
�
Change in monocytes
0 (n=12) 2.22±1.75
� -0.28±9.04 -0.22±1.60
�
1 (n= 8) 4.12±2.04
� 2.43±6.62 -1.70±0.41
�
Table 3. Ghrelin and TNF-a changes according to inflammato-
ry cell changes of both groups 5 weeks later*
*Data are expressed as the mean±SD. Change means the value dif-
ference of all the variables measured from baseline to follow-up exami-
nation.
� P<0.01; 
� P<0.05.
TNF-a, tumor necrosis factor-a.
*Data are expressed as the mean±SD.
Treatment group (n=9)
Pre-treatment Post-treatment P value Pre-treatment Post-treatment P value
Parameters
Control group (n=11)
Ghrelin/obestatin ratio mRNA expression in fundus 1.03±0.26 1.07±0.22 NS 1.02±0.66 0.88±0.30 NS
Ghrelin/obestatin ratio mRNA expression in antrum 2.15±2.28 2.06±1.44 NS 3.20±4.18 2.41±1.64 NS
Plasma ghrelin obestatin ratio (pg/mL) 2.31±0.44 3.01±0.99 0.06 2.65±0.90 2.89±2.47 NS
Table 4. Changes in plasma ghrelin/obestatin ratio and ghrelin/obestatin ratio of gastric mRNA expression levels before and after fol-
low up*
Fig. 3. The changes of gastric ghrelin mRNA expression levels in the treatment group before and after H. pylori eradication therapy (A)
and in the control group between baseline and 5 weeks later (B).
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A Btic ulcers in order to minimize the confounding factors and
found that ghrelin production increased after H. pylori erad-
ication, independent of inflammation. 
We found that plasma ghrelin in the treatment group in-
creased after H. pylori eradications were not statistically sig-
nificant. If there is an H. pylori eradication effect in appetite
control, it could be caused by the activation of the ghrelin
receptor in gastric mucosa. However, the function of ghre-
lin is not well understood. This result is similar to that of a
Japanese study in which Isomoto et al. (11) showed that the
plasma ghrelin level did not change after treating H. pylori
infections (18, 23). In contrast, Nwokolo et al. showed a clear
increase of plasma ghrelin levels after H. pylori treatment.
Those results led to some confusion. Cumming (24) suggest-
ed that the results were inconsistent because the subjects in
the study by Nwokolo et al. were younger and probably had
a shorter duration of H. pylori infection, which might have
produced a different treatment response than that in the study
by Isomoto et al. Our subjects were middle-aged, much older
than those in Nwokolo’s study, and our results are similar to
those of the Japanese study. 
We recruited healthy subjects with gastritis in order to
eliminate the effect of severe inflammation, such as gastric
ulcers. However, we observed a reduction of inflammation
in the gastric mucosa after H. pylori eradication. Although
neutrophil infiltration clears rapidly after H. pylori eradica-
tion, mononuclear cell invasion persists for 6 months to 1
yr, and recovery from glandular atrophy takes even longer, if
it occurs at all (25). In addition, mononuclear infiltration,
which is associated with glandular atrophy, changed slight-
ly on follow up examination (12, 18). Thus, we could expect
the change of ghrelin mRNA expression to continue to in-
crease with the reduction of inflammation after treatment.
However, a long-term follow-up study of H. pylori eradica-
tion is necessary to test this hypothesis. 
A previous study reported that body weight and BMI in-
creased significantly 12 months after the eradication of H.
pylori (5). Our study was designed to evaluate the change in
ghrelin production at 4 weeks after H. pylori eradication and
therefore was too short to detect a change in BMI. 
Obestatin, although derived from the same peptide pre-
cursor as ghrelin, was initially reported to antagonize the ac-
tion of ghrelin by activating orphan G protein-coupled re-
ceptor 39 (14). Since the original study, two studies have par-
tially confirmed the effects of obestatin on food intake and
gastric emptying (26, 27), but two other studies have failed
to replicate the findings (28, 29). A recent study has linked
obestatin to obesity in humans, showing that fasting plas-
ma obestatin was significantly suppressed in obese subjects
(15, 16) and increased as weight was lost. This was paralleled
by increases in circulating ghrelin concentrations. Guo et al.
(15) suggested that the circulating preprandial ghrelin-to-
obestatin ratio is elevated in obese humans. Vicennati et al.
(30) study showed that in the presence of obesity, women had
a decreased ghrelin/obestatin ratio. Based on available data,
it is difficult to explain these disparate findings. Differences
in the obese status could partially explain such disparate obe-
statin values. However, these findings may support the hypoth-
esis that obese individuals with an imbalance of ghrelin and
obestatin levels even though the results are inconsistent.
In the present study, the post-treatment plasma ghrelin/
obestatin ratio increased, although insignificantly (from 2.31
±0.44 to 3.01±1.00, P=0.06). There was a small differ-
ence in the obestatin mRNA expression level of gastric an-
trum after H. pylori eradication, which didn’t influence the
plasma level of obestatin. The stomach is considered an im-
portant organ for obestatin secretion because obestatin can
be purified from the stomach and tends to be lower in gas-
trectomy patients (16). It is not surprising that H. pylori in-
fection or its treatment can affect gastric obestatin produc-
tion. However, our results did not provide evidence suggest-
ing that obestatin production is associated with H. pylori era-
dication.
In summary, we demonstrated that ghrelin mRNA expres-
sion in the gastric mucosa increased after H. pylori eradica-
tion. We also suggest a hypothesis that H. pylori eradication
is associated with a change in ghrelin in the gastric mucosa,
regardless of inflammation. However, we could not demon-
strate a clear association with obestatin. Our study was too
short in duration to evaluate changes in BMI and long term
changes of the ghrelin in gastric mucosa after H. pylori erad-
ication. A follow-up study of longer duration is needed.
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